AMENDMENTS TO THE CLAIMS

1-22. (canceled)

23. (currently amended) A method for treating ~~impaired respiratory function in a human patient suffering from~~ sleep apnea in a human patient, comprising administering to said patient an effective amount of gaboxadol per day.

24. (canceled)

25. (previously presented) The method of claim 23, wherein the sleep apnea is central sleep apnea.

26. (previously presented) The method of claim 23, wherein the sleep apnea is obstructive sleep apnea.

27. (previously presented) The method of claim 23, wherein the sleep apnea is a mix of central sleep apnea and obstructive sleep apnea.

28. (previously presented) The method of claim 23, wherein the gaboxadol increases slow wave sleep in the patient and thereby improves the respiratory function.

29. (previously presented) The method of claim 23, wherein the human patient suffers from sleep apnea and depression at the same time.

30. (previously presented) The method of claim 23, wherein the gaboxadol is in the form of an acid addition salt, a zwitter ion hydrate, or a zwitter ion anhydrate.

31. (previously presented) The method of claim 23, wherein the gaboxadol is in the form of its hydrochloride or hydrobromide salt.

32. (previously presented) The method of claim 23, wherein the gaboxadol is in the form of its zwitter ion monohydrate.

33. (previously presented) The method of claim 23, wherein the gaboxadol is administered orally.

34. (previously presented) The method of claim 23, wherein the gaboxadol is administered in the form of an oral dosage form.

35. (previously presented) The method of claim 34, wherein the oral dosage form is a solid dosage form.

36. (previously presented) The method of claim 35, wherein the oral dosage form is a tablet or capsule.

37. (previously presented) The method of claim 34, wherein the oral dosage form is a liquid dosage form.

38. (previously presented) The method of claim 34, wherein the oral dosage form comprises from 2.5 mg to 20 mg of gaboxadol.

39. (previously presented) The method of claim 23, wherein the human patient is selected from elderly or adults.

40. (currently amended) The method of claim 23, wherein said treatment is given for a period of less than a week ~~intermediate term treatment~~.

41. (currently amended) The method of claim 23, wherein said treatment is given for a period of 1 to 4 weeks ~~short term treatment~~.

42. (currently amended) The method of claim 23, wherein said treatment is given for a period exceeding 4 weeks ~~long term treatment~~.

43. (previously presented) The method of claim 23, wherein said gaboxadol is crystalline.

44. (previously presented) The method of claim 34, wherein the dosage form comprises an amount of from 2.5 mg to 20 mg of gaboxadol, said amount being effective during a substantial portion of a single sleep period.

45. (previously presented) The method of claim 44, wherein the dosage form comprises 5 mg to 15 mg of gaboxadol.

46. (previously presented) The method of claim 44, wherein said substantial portion is 50% or more.

47. (previously presented) The method of claim 46, wherein said substantial portion is 80% or more.

48. (previously presented) The method of claim 44, wherein said single sleep period is from one to eight hours.

49. (previously presented) The method of claim 44, wherein the amount of gaboxadol is released from a composition for controlled release.

50. (previously presented) The method of claim 49, wherein from 50% to 100% of the amount of gaboxadol is released within a period of three hours from administration.

51. (previously presented) The method of claim 49, wherein from 80% to 100% of the amount of gaboxadol is released within a period of five hours from administration.